What You Should Know: – Veradigm, a provider of healthcare data and technology solutions, today announced a significant advancement in the application of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for the increasingly prevalent GLP-1 receptor agonists (GLP-1 RAs), including widely used medications like semaglutide and tirzepatide. By deploying AI algorithms … Read more
(MedPage Today) — Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial. By week 72, participants on the dual GIP/GLP-1 receptor agonist tirzepatide lost 20.2% of body weight…
President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and enforcement actions. The move tasks HHS Secretary Robert F. Kennedy Jr. with setting target prices to bring U.S. drug costs “in line with comparably … Read more
For years, researchers had been searching for hormones that promote insulin secretion. These hormones, known as incretins, could be the key to helping treat type 2 diabetes (T2D). In the 1980s, glucagon-like peptide-1 (GLP-1) was found to be an incretin secreted by L-cells in the small intestine and to inhibit glucagon secretion. However, because of … Read more
MONDAY, May 12, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and Metabolism and presented at the annual meeting of…
This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted … Read more
Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms Pittsburgh Post-Gazette Eli Lilly Sues 4 Telehealth Cos. For Weight Loss Drug Copies Law360 Big Pharma Is Winning the Price War Over Weight Loss Drugs Like Ozempic: Will RFK Jr. and His MAHA Allies Push Back? The New York Sun Navigating The GLP-1 Litigation Landscape Life … Read more
TWO blockbuster weight loss just have been tested against each other for the first time in a head-to-head trial. There was a clear winner, which saw slimmers shed 20 per cent of their body weight. AlamyMounjaro helped users lose up to 20 per cent of their body weight[/caption] AlamyMeanwhile, Wegovy saw people lose 13 per … Read more
New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits
INDIANAPOLIS, May 11, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1…